[go: up one dir, main page]

MX2019003374A - Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. - Google Patents

Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa.

Info

Publication number
MX2019003374A
MX2019003374A MX2019003374A MX2019003374A MX2019003374A MX 2019003374 A MX2019003374 A MX 2019003374A MX 2019003374 A MX2019003374 A MX 2019003374A MX 2019003374 A MX2019003374 A MX 2019003374A MX 2019003374 A MX2019003374 A MX 2019003374A
Authority
MX
Mexico
Prior art keywords
topoisomerase inhibitor
prevent
vda
treat cancer
cancer including
Prior art date
Application number
MX2019003374A
Other languages
English (en)
Other versions
MX392672B (es
Inventor
Jin Kim Soo
Sang Kim Young
Kim Minchae
Whan PARK Young-
Yong KIM Jung-
Cull Kim In
Chull Kim In
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2019003374A publication Critical patent/MX2019003374A/es
Publication of MX392672B publication Critical patent/MX392672B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona a una composición combinada farmacéutica para prevenir o tratar cáncer que comprende un compuesto de la fórmula 1 o una sal farmacéuticamente aceptable del mismo e inhibidor de topoisomerasa como ingredientes activos. La composición combinada farmacéutica de la presente invención específicamente inhibe la proliferación celular e induce apoptosis en cuanto a varios cánceres tales como cáncer colorrectal y cáncer de ovario que un agente de interrupción vascular no puede tratar debido a un mecanismo de inhibición complejo de neoplasma del compuesto de la fórmula 1 y la sal farmacéuticamente aceptable del mismo e inhibidor de topoisomerasa, y mediante lo cual se puede utilizar útilmente para prevenir y tratar cáncer.
MX2019003374A 2016-09-26 2017-09-08 Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. MX392672B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662400054P 2016-09-26 2016-09-26
US15/447,247 US9980953B2 (en) 2016-09-26 2017-03-02 Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
PCT/KR2017/009889 WO2018056620A1 (en) 2016-09-26 2017-09-08 Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda and topoisomerase inhibitor

Publications (2)

Publication Number Publication Date
MX2019003374A true MX2019003374A (es) 2019-12-16
MX392672B MX392672B (es) 2025-03-24

Family

ID=61688111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003374A MX392672B (es) 2016-09-26 2017-09-08 Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa.

Country Status (17)

Country Link
US (1) US9980953B2 (es)
EP (1) EP3515443B1 (es)
JP (1) JP6894516B2 (es)
KR (2) KR20190039325A (es)
CN (1) CN109789136B (es)
AU (1) AU2017330814B2 (es)
BR (1) BR112019005898A2 (es)
CA (1) CA3037836C (es)
DK (1) DK3515443T3 (es)
ES (1) ES2922752T3 (es)
HU (1) HUE059876T2 (es)
MX (1) MX392672B (es)
PL (1) PL3515443T3 (es)
PT (1) PT3515443T (es)
RU (1) RU2724341C1 (es)
WO (1) WO2018056620A1 (es)
ZA (1) ZA201902339B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
WO2004091620A1 (en) 2003-04-18 2004-10-28 Pharmacia Italia S.P.A. Combined therapy comprising an indolopyrrolocarbazole derivative and irinotecan
AU2005249201A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
KR100932093B1 (ko) * 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US20090149397A1 (en) 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
CA2719243C (en) 2008-03-26 2013-06-25 Chong Kun Dang Pharmaceutical Corp. Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
EP2773345A1 (en) * 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors

Also Published As

Publication number Publication date
WO2018056620A1 (en) 2018-03-29
ZA201902339B (en) 2020-08-26
PL3515443T3 (pl) 2022-10-03
RU2724341C1 (ru) 2020-06-23
KR20190039325A (ko) 2019-04-10
US20180085363A1 (en) 2018-03-29
CA3037836C (en) 2022-03-22
EP3515443A1 (en) 2019-07-31
JP6894516B2 (ja) 2021-06-30
CN109789136B (zh) 2021-12-21
KR20210046868A (ko) 2021-04-28
ES2922752T3 (es) 2022-09-20
KR102276343B1 (ko) 2021-07-12
AU2017330814B2 (en) 2020-04-30
DK3515443T3 (da) 2022-09-12
BR112019005898A2 (pt) 2019-06-11
HUE059876T2 (hu) 2023-01-28
EP3515443B1 (en) 2022-06-22
MX392672B (es) 2025-03-24
CA3037836A1 (en) 2018-03-29
AU2017330814A1 (en) 2019-05-02
EP3515443A4 (en) 2020-05-13
CN109789136A (zh) 2019-05-21
US9980953B2 (en) 2018-05-29
PT3515443T (pt) 2022-07-12
JP2019529556A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
NZ784224A (en) Parp1 inhibitors
ZA202007007B (en) Mcl-1 inhibitors
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
CL2018003511A1 (es) Derivados de pirazolopirimidina como inhibidor de quinasa.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
TW201613887A (en) Antiproliferative compounds and methods of use thereof
ECSP17029203A (es) Inhibidor de cinasa aurora a
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX389250B (es) Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MX2020004374A (es) Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
EA201891439A1 (ru) Трициклические соединения и их композиции в качестве ингибиторов киназ
EA201792288A1 (ru) Способы лечения рака
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2